Literature DB >> 32610095

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.

Tae Gyu Oh1, Susy M Kim2, Cyrielle Caussy3, Ting Fu1, Jian Guo4, Shirin Bassirian2, Seema Singh2, Egbert V Madamba2, Ricki Bettencourt5, Lisa Richards2, Ruth T Yu1, Annette R Atkins1, Tao Huan4, David A Brenner6, Claude B Sirlin7, Michael Downes1, Ronald M Evans8, Rohit Loomba9.   

Abstract

Dysregulation of the gut microbiome has been implicated in the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis and cirrhosis. To determine the diagnostic capacity of this association, we compared stool microbiomes across 163 well-characterized participants encompassing non-NAFLD controls, NAFLD-cirrhosis patients, and their first-degree relatives. Interrogation of shotgun metagenomic and untargeted metabolomic profiles by using the random forest machine learning algorithm and differential abundance analysis identified discrete metagenomic and metabolomic signatures that were similarly effective in detecting cirrhosis (diagnostic accuracy 0.91, area under curve [AUC]). Combining the metagenomic signature with age and serum albumin levels accurately distinguished cirrhosis in etiologically and genetically distinct cohorts from geographically separated regions. Additional inclusion of serum aspartate aminotransferase levels, which are increased in cirrhosis patients, enabled discrimination of cirrhosis from earlier stages of fibrosis. These findings demonstrate that a core set of gut microbiome species might offer universal utility as a non-invasive diagnostic test for cirrhosis.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NAFLD; NASH; biomarker; cirrhosis; fatty liver; liver fibrosis; metabolomics; metagenomics; microbiome; microbiota; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis

Mesh:

Substances:

Year:  2020        PMID: 32610095      PMCID: PMC7822714          DOI: 10.1016/j.cmet.2020.06.005

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  46 in total

Review 1.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

Review 2.  Altered Microbiome in Patients With Cirrhosis and Complications.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

3.  Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Min-Tzu Lo; Amy Liu; Ricki Bettencourt; Veeral H Ajmera; Shirin Bassirian; Jonathan Hooker; Ethan Sy; Lisa Richards; Nicholas Schork; Bernd Schnabl; David A Brenner; Claude B Sirlin; Chi-Hua Chen; Rohit Loomba
Journal:  Hepatology       Date:  2018-05-20       Impact factor: 17.425

4.  Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.

Authors:  Z Permutt; T-A Le; M R Peterson; E Seki; D A Brenner; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-05-03       Impact factor: 8.171

5.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

6.  Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.

Authors:  Cyrielle Caussy; Mosab H Alquiraish; Phirum Nguyen; Carolyn Hernandez; Sandra Cepin; Lynda E Fortney; Veeral Ajmera; Ricki Bettencourt; Summer Collier; Jonathan Hooker; Ethan Sy; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2018-02-19       Impact factor: 17.425

7.  Alterations of the human gut microbiome in liver cirrhosis.

Authors:  Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

8.  Mass spectrometry searches using MASST.

Authors:  Mingxun Wang; Alan K Jarmusch; Fernando Vargas; Alexander A Aksenov; Julia M Gauglitz; Kelly Weldon; Daniel Petras; Ricardo da Silva; Robert Quinn; Alexey V Melnik; Justin J J van der Hooft; Andrés Mauricio Caraballo-Rodríguez; Louis Felix Nothias; Christine M Aceves; Morgan Panitchpakdi; Elizabeth Brown; Francesca Di Ottavio; Nicole Sikora; Emmanuel O Elijah; Lara Labarta-Bajo; Emily C Gentry; Shabnam Shalapour; Kathleen E Kyle; Sara P Puckett; Jeramie D Watrous; Carolina S Carpenter; Amina Bouslimani; Madeleine Ernst; Austin D Swafford; Elina I Zúñiga; Marcy J Balunas; Jonathan L Klassen; Rohit Loomba; Rob Knight; Nuno Bandeira; Pieter C Dorrestein
Journal:  Nat Biotechnol       Date:  2020-01       Impact factor: 54.908

9.  Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome.

Authors:  Rachel J Perry; Liang Peng; Natasha A Barry; Gary W Cline; Dongyan Zhang; Rebecca L Cardone; Kitt Falk Petersen; Richard G Kibbey; Andrew L Goodman; Gerald I Shulman
Journal:  Nature       Date:  2016-06-09       Impact factor: 49.962

10.  A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Anupriya Tripathi; Greg Humphrey; Shirin Bassirian; Seema Singh; Claire Faulkner; Ricki Bettencourt; Emily Rizo; Lisa Richards; Zhenjiang Z Xu; Michael R Downes; Ronald M Evans; David A Brenner; Claude B Sirlin; Rob Knight; Rohit Loomba
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

View more
  39 in total

Review 1.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

Review 2.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

3.  Integrated omics analysis: the relationship between significantly increased Klebsiella post-hepatectomy and decreased hub-metabolite 3-methyl-2-oxobutanoic acid is associated with induced liver failure.

Authors:  Yu-Chong Peng; Xin-Hua Zhao; Chuan-Fa Zeng; Jing-Xuan Xu; Lu-Nan Qi; Le-Qun Li
Journal:  J Gastrointest Oncol       Date:  2022-02

4.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

5.  Comprehensive Analysis of Gut Microbiota and Fecal Bile Acid Profiles in Children With Biliary Atresia.

Authors:  Ting Yang; Shen Yang; Jiawei Zhao; Peize Wang; Siqi Li; Yuyan Jin; Zhaozhou Liu; Xinyue Zhang; Yanan Zhang; Yong Zhao; Junmin Liao; Shuangshuang Li; Kaiyun Hua; Yichao Gu; Dingding Wang; Jinshi Huang
Journal:  Front Cell Infect Microbiol       Date:  2022-06-17       Impact factor: 6.073

6.  iNetModels 2.0: an interactive visualization and database of multi-omics data.

Authors:  Muhammad Arif; Cheng Zhang; Xiangyu Li; Cem Güngör; Buğra Çakmak; Metin Arslantürk; Abdellah Tebani; Berkay Özcan; Oğuzhan Subaş; Wenyu Zhou; Brian Piening; Hasan Turkez; Linn Fagerberg; Nathan Price; Leroy Hood; Michael Snyder; Jens Nielsen; Mathias Uhlen; Adil Mardinoglu
Journal:  Nucleic Acids Res       Date:  2021-07-02       Impact factor: 16.971

Review 7.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

8.  Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD.

Authors:  Na Jiao; Rohit Loomba; Zi-Huan Yang; Dingfeng Wu; Sa Fang; Richele Bettencourt; Ping Lan; Ruixin Zhu; Lixin Zhu
Journal:  Physiol Genomics       Date:  2021-06-21       Impact factor: 4.297

Review 9.  Bile Acids, Their Receptors, and the Gut Microbiota.

Authors:  James C Poland; C Robb Flynn
Journal:  Physiology (Bethesda)       Date:  2021-07-01

10.  Microbial DNA Enrichment Promotes Adrenomedullary Inflammation, Catecholamine Secretion, and Hypertension in Obese Mice.

Authors:  Hong Gao; Zhongmou Jin; Kechun Tang; Yudong Ji; Jorge Suarez; Jorge A Suarez; Karina Cunha E Rocha; Dinghong Zhang; Wolfgang H Dillmann; Sushil K Mahata; Wei Ying
Journal:  J Am Heart Assoc       Date:  2022-02-03       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.